Efficacy of a Convective Prewarming System in Prevention of Perioperative Hypothermia
NCT ID: NCT01502163
Last Updated: 2012-03-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
90 participants
INTERVENTIONAL
2011-10-31
2012-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
For not long lasting surgery without specific risk for hypothermia the standard procedure for prevention of perioperative hypothermia is insulation. However, the insulation is often not effective enough to prevent intra- and postoperative hypothermia. The implementation of a prewarming is difficult because of variable OR schedules and therefore not often applied.
In the planed prospective, multicenter, randomised-controlled trial will the efficacy of a convective prewarming system on prevention of intra- and perioperative hypothermia (Thermoflect™, TSCI, Amersfoort, NL) be compared to an intraoperative application of forced air warming with or without passive insulation before induction of anesthesia.
The studied prewarming device is easy to use and will be applied on the nursery ward 30-60 minutes before transfer of the patient to the OR.
Perioperative hypothermia is a common complication in general aesthesia. Perioperative hypothermia is associated with medical risks as intraoperative impaired coagulation due to reversible platelet dysfunction, a prolonged bleeding time and increased intraoperative blood loss. In the postoperative course the perioperative hypothermia is especially for patients with cardiopulmonary diseases a relevant problem. Not at least sensual cold and shivering is uncomfortable for the patient.
The study is conducted as a multicenter, prospective, randomised controlled trial. All patients will receive intraoperatively a forced air warming device (Termoflect™/Mistral Air ™). For one intervention group will additionally the insulation with the Thermoflect™ will be applied on nursery ward, the second intervention group will receive additionally a convective air warmer/ reflective blanket (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL) preoperatively on study day on nursery ward.
The aim of the study is to prove the hypothesis that a preoperative insulation with a commercial insulation material (Thermoflect™, TSCI, Amersfoort, NL) leads to a lower incidence of perioperative hypothermia in general anesthesia. The second hypothesis is, that an active prewarming (Thermoflect™ with Mistral Air™, TSCI, Amersfoort, NL) is associated with a more less incidence of periopative hypothermia.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevention of Perioperative Hypothermia in Transurethral Resection Under Spinal Anaesthesia
NCT04252820
Prevention of Perioperative Hypothermia in Patients Submitted to Transurethral Resection
NCT03630887
Effect of Prewarming on Microcirculatory Response
NCT02186210
Effects of Active Prewarming in Perioperative Hypothermia in Adults
NCT04033900
Pre Warming Protocol Implementation in Operation Room
NCT05573152
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
* No prewarming
* Intraoperative forced air warming (Thermoflect™/Mistral Air™) (after induction of anaesthesia, before surgery starting)
* Passive insulation with Thermoflect™ material.
* All fluids administrated intraoperative will be warmed.
No interventions assigned to this group
Group passive prewarming
* Passive prewarming / insulation on nursery ward before transport to the OR (Thermoflect TSCI, Amersfoort, NL)
* Intraoperative forced air warming (Thermoflect™ / Mistral Air ™) The forced air warming will be applied after induction of anaesthesia.
* All fluids administrated intraoperative will be warmed.
Thermoflect [TM] passive insulation
passive insulation in the preoperative phase, befor induction of anesthesia
Group Active prewarming
* Active prewarming on nursery ward before transport to the OR (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)
* Intraoperative forced air warming (Thermoflect™ / Mistral Air ™) The forced air warming will be applied after induction of anaesthesia.
* All fluids administrated intraoperative will be warmed.
Active prewarming (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)
Prewarming Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL before induction of anesthesia
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Thermoflect [TM] passive insulation
passive insulation in the preoperative phase, befor induction of anesthesia
Active prewarming (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)
Prewarming Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL before induction of anesthesia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI from 20 to 30 kg/m2
* Risk class ASA I to III
* Scheduled time for surgery 30 to 120 minutes
* Scheduled anaesthesia with remifentanil, propofol, rocuronium and sevofluran
* Ability of informed consent
Exclusion Criteria
* Risk class ASA IV to V
* Hypo- and Hyperthyroidism
* Febrile infection
* Pregnancy
* Scheduled time for surgery \< 30 or \> 120 minutes
* Known incompatibility for midazolam, remifentanil, propofol oder rocuronium
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UZ Gent, Belgium
UNKNOWN
Policlinica de Guipuzcoa, San Sebastian, Spain
UNKNOWN
University of Göttingen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. T. Perl
Principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michel Quintel, Prof
Role: STUDY_CHAIR
University Göttingen, Germany
Thorsten Perl, MD
Role: PRINCIPAL_INVESTIGATOR
University Göttingen, Germany
Koen Reyntjens, MD
Role: PRINCIPAL_INVESTIGATOR
UZ Gent, Belgium
Juan Zamballos, Prof.
Role: PRINCIPAL_INVESTIGATOR
Policlinica de Guipuzcoa, San Sebastian, Spain
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UZ Gent
Ghent, , Belgium
Department of Anesthesiology, Emergency- and Intensive Care Medicine
Göttingen, , Germany
Policlinica de Guipuzcoa
Donostia / San Sebastian, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11/4/11
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.